- Home
- CNC vs RVMD Comparison
CNC vs RVMD Comparison
Compare CNC & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNC | RVMD |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 30.1B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNC | RVMD |
|---|---|---|
| Price | $65.07 | $208.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 19 |
| Target Price | $46.75 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.30 | N/A |
| Revenue | ★ $194,777,000,000.00 | N/A |
| Revenue This Year | $8.31 | N/A |
| Revenue Next Year | $1.05 | $533.02 |
| P/E Ratio | $12.14 | ★ N/A |
| Revenue Growth | ★ 19.44 | N/A |
| 52 Week Low | $28.24 | $38.50 |
| 52 Week High | $69.36 | $224.31 |
Technical Indicators
Market Signals| Indicator | CNC | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 55.03 |
| Support Level | $63.34 | $177.04 |
| Resistance Level | $69.01 | $220.34 |
| Average True Range (ATR) | 1.70 | 8.60 |
| MACD | -0.09 | -1.27 |
| Stochastic Oscillator | 37.67 | 38.49 |
Price Performance
Historical ComparisonAbout CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.